Preliminary evidence that fatigue contributes to anhedonia in stable individuals diagnosed with schizophrenia.
anhedonia
depression
fatigue impact
primary and secondary negative symptoms
schizophrenia
Journal
Frontiers in psychiatry
ISSN: 1664-0640
Titre abrégé: Front Psychiatry
Pays: Switzerland
ID NLM: 101545006
Informations de publication
Date de publication:
2023
2023
Historique:
received:
15
11
2022
accepted:
11
01
2023
entrez:
13
2
2023
pubmed:
14
2
2023
medline:
14
2
2023
Statut:
epublish
Résumé
Anhedonia and fatigue are trans-diagnostic symptoms commonly observed in schizophrenia. Anhedonia is a core negative symptom with a strong relationship with depression and is associated with diminished global functioning. Similarly, fatigue is also associated to depression and research across psychiatric illnesses indicate that fatigue may persist even when primary symptoms are treated. Although fatigue is common in people diagnosed with schizophrenia, it is under studied within this population. The objective of this exploratory study was to investigate the association of fatigue and anhedonia by controlling for depression in a sample of individuals diagnosed with schizophrenia. Fifty-one stable individuals diagnosed with schizophrenia from the University Department of Adult Psychiatry in Montpellier took part in this study. Participants completed questionnaires on fatigue impact and depression, and were assessed for symptom severity. Following data collection, statistical analyses were conducted in order to explore associations between clinical variables and fatigue impact. Based on the results obtained, a hierarchical linear regression was conducted in order to investigate whether fatigue impact contributed to the variance of negative symptoms. The hierarchical linear regression indicated that when controlling for depression, fatigue impact contributes to ~20% of the variance of anhedonia. Together the social impact of fatigue and depression contribute to 24% of the variation of anhedonia. To the best of our knowledge, this exploratory study is the first to investigate and show that fatigue impact may contribute to anhedonia. We recommend further research to investigate fatigue, its impact on symptomatology, and better categorization of negative symptoms in hopes of developing targeted fatigue treatment interventions.
Identifiants
pubmed: 36778632
doi: 10.3389/fpsyt.2023.1098932
pmc: PMC9911435
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1098932Informations de copyright
Copyright © 2023 Laraki, Bayard, Decombe, Capdevielle and Raffard.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Schizophr Res. 2000 May 5;42(3):231-9
pubmed: 10785581
Schizophr Bull. 2006 Apr;32(2):259-73
pubmed: 16221997
CNS Neurosci Ther. 2018 Jul;24(7):615-623
pubmed: 29687627
Am J Psychiatry. 2000 Sep;157(9):1379-89
pubmed: 10964850
Global Health. 2020 Dec 18;16(1):119
pubmed: 33339523
Arch Gen Psychiatry. 1995 May;52(5):352-60
pubmed: 7726715
Schizophr Bull. 2010 Nov;36(6):1115-30
pubmed: 19386576
Depress Anxiety. 2014 Mar;31(3):250-7
pubmed: 24115209
Br J Psychiatry. 2014 Jan;204(1):20-9
pubmed: 24385461
Arch Gen Psychiatry. 1961 Jun;4:561-71
pubmed: 13688369
Schizophr Res. 2003 Dec 15;65(2-3):125-37
pubmed: 14630305
J Clin Psychiatry. 2006;67 Suppl 6:9-15
pubmed: 16848671
Schizophr Res. 2011 Nov;132(2-3):140-5
pubmed: 21798716
Schizophr Res. 2018 Feb;192:148-153
pubmed: 28599750
Neuropsychiatr Dis Treat. 2020 Feb 21;16:519-534
pubmed: 32110026
NPJ Schizophr. 2021 Feb 15;7(1):11
pubmed: 33589645
Schizophr Res Treatment. 2013;2013:425826
pubmed: 23738067
Mult Scler. 2007 Sep;13(8):1026-32
pubmed: 17895294
Schizophr Bull. 2006 Apr;32(2):238-45
pubmed: 16254064
Acta Psychiatr Scand. 1999 Aug;100(2):105-18
pubmed: 10480196
Psychosom Med. 2014 Jun;76(5):379-88
pubmed: 25076512
Schizophr Res. 2006 Jul;85(1-3):273-9
pubmed: 16730430
Schizophr Res. 2014 Mar;153(1-3):64-7
pubmed: 24439270
Curr Top Behav Neurosci. 2022;58:255-277
pubmed: 35435648
Schizophr Bull. 2015 Jul;41(4):892-9
pubmed: 25528757
Clin Infect Dis. 1994 Jan;18 Suppl 1:S79-83
pubmed: 8148458
Int J Neuropsychopharmacol. 2023 Jan 19;26(1):9-19
pubmed: 35999024
Br J Psychiatry Suppl. 1989 Nov;(7):49-58
pubmed: 2695141
Front Psychiatry. 2022 Jan 03;12:766692
pubmed: 35046851
Aust N Z J Psychiatry. 2012 Aug;46(8):735-52
pubmed: 22696547
Curr Opin Psychiatry. 2015 Jan;28(1):7-12
pubmed: 25415499
Eur Psychiatry. 2021 Feb 18;64(1):e23
pubmed: 33597064
Schizophr Bull. 2006 Apr;32(2):214-9
pubmed: 16481659
Community Ment Health J. 2015 Apr;51(3):377-82
pubmed: 24972909
Schizophr Bull. 2012 Mar;38(2):247-57
pubmed: 22258882
Schizophr Res. 2004 Apr 1;67(2-3):185-94
pubmed: 14984877
Schizophr Bull. 2011 Mar;37(2):300-5
pubmed: 20558531
Schizophr Bull. 2009 Mar;35(2):383-402
pubmed: 19011234
Schizophr Bull. 1987;13(2):261-76
pubmed: 3616518
Am J Psychiatry. 2017 Oct 1;174(10):927-942
pubmed: 28541090
Trials. 2020 Sep 17;21(1):797
pubmed: 32943079
Psychiatriki. 2011 Oct-Dec;22(4):320-9
pubmed: 22271845
Acta Psychiatr Scand. 1999 Sep;100(3):237-43
pubmed: 10493091
BMC Psychiatry. 2015 Sep 29;15:231
pubmed: 26419356
Schizophr Bull. 2011 Sep;37 Suppl 2:S98-110
pubmed: 21860053
J Psychiatr Res. 2022 Mar;147:274-282
pubmed: 35074744
Am J Psychiatry. 2013 Feb;170(2):165-72
pubmed: 23377637
BBA Clin. 2014 Jun 1;1:12-23
pubmed: 25147756
Acta Psychiatr Scand. 2018 May;137(5):380-390
pubmed: 29532909
Clin Psychol Rev. 2013 Dec;33(8):914-28
pubmed: 23988452
Int J Neuropsychopharmacol. 2021 Nov 12;24(11):859-866
pubmed: 34077523
Int Clin Psychopharmacol. 1999 May;14(3):153-65
pubmed: 10435768
Occup Med (Lond). 2010 Mar;60(2):159
pubmed: 20157190
Clin Psychol Rev. 2021 Apr;85:102000
pubmed: 33721606
Psychol Med. 2016 Oct;46(14):2869-2881
pubmed: 27502153
Metabolism. 2010 Sep;59(9):1351-7
pubmed: 20102774
Schizophr Bull. 2016 May;42(3):571-8
pubmed: 26564898
Eur Arch Psychiatry Clin Neurosci. 2015 Oct;265(7):567-78
pubmed: 25895634
Transl Psychiatry. 2020 Aug 7;10(1):273
pubmed: 32769967
Schizophr Res. 2017 Aug;186:29-38
pubmed: 27230288
J Psychiatr Res. 2012 Mar;46(3):370-4
pubmed: 22236834
Brain. 2011 Jun;134(Pt 6):1751-64
pubmed: 21482548
J Psychopharmacol. 2011 May;25(5):567-620
pubmed: 21292923
Eur Arch Psychiatry Clin Neurosci. 2016 Aug;266(5):387-96
pubmed: 27107764
Schizophr Res. 2017 Aug;186:55-62
pubmed: 27293137
J Affect Disord. 2012 Sep;140(1):38-47
pubmed: 22099566
Eur Psychiatry. 2003 Aug;18(5):226-32
pubmed: 12927323
Neuropsychology. 2015 Sep;29(5):675-82
pubmed: 25643212
Int Clin Psychopharmacol. 1999 May;14(3):139-51
pubmed: 10435767
J Pers. 2011 Dec;79(6):1315-32
pubmed: 21480908
Schizophr Res. 2012 May;137(1-3):190-5
pubmed: 22386735
Schizophr Res. 2006 Jul;85(1-3):280-7
pubmed: 16730429